title: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.
abstract: BACKGROUND
  The purpose of the present study was to systematically review the effect of cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and interstitial lung disease.
  
  
  METHODS
  The primary outcomes were the mean change in forced vital capacity and in diffusing capacity for carbon monoxide after 12 months of therapy in patients treated with cyclophosphamide.
  
  
  RESULTS
  Three randomized clinical trials and six prospective observational studies were included for analysis. In the pooled analysis, the forced vital capacity and the diffusing capacity for carbon monoxide predicted values after 12 months of therapy were essentially unchanged, with mean changes of 2.83% (95% confidence interval = 0.35 to 5.31) and 4.56% (95% confidence interval = -0.21 to 9.33), respectively.
  
  
  CONCLUSIONS
  Cyclophosphamide treatment in patients with systemic sclerosis-related interstitial lung disease does not result in clinically significant improvement of pulmonary function.
authors.affiliation: Division of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. nannini.carlotta@mayo.edu
authors.forename: Carlotta
authors.initials: C
authors.lastname: Nannini
authors.forename: Colin P
authors.initials: CP
authors.lastname: West
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Erwin
authors.forename: Eric L
authors.initials: EL
authors.lastname: Matteson
mesh_terms: D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008168:Lung / Q000187:drug effects*; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000209:etiology; D012129:Respiratory Function Tests; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide